eligibility_summary
Adults ≥18 with aggressive B‑cell NHL (e.g., DLBCL/transformed), relapsed/refractory after ≥2 lines, measurable disease (≥2 lesions), ECOG 0–2, adequate organ/hematologic function, life expectancy ≥12 wks, tissue for part 2. G1: naïve to CD3xCD20, G2: no standard options (prior CAR‑T/bispecific allowed). Exclude: CNS lymphoma, recent therapy, prior PIM inhibitor, recent major surgery/HSCT, immune suppression/autoimmune, active infection/HIV/liver disease, pneumonitis/IBD, CYP2D6/BCRP drugs, cardiac/QTc/arrhythmia, pregnancy, allergies.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06534437 (Phase 2) in relapsed/refractory aggressive B‑cell NHL tests: 1) MEN1703 (dapolsertib, SEL24) – an oral small‑molecule dual kinase inhibitor of PIM kinases and FLT3, used as monotherapy (Group 2) and combined with glofitamab (Group 1), with an optional randomized comparison vs glofitamab alone. 2) Glofitamab – a T‑cell–engaging bispecific monoclonal antibody that binds bivalently to CD20 on B cells and monovalently to CD3 on T cells to redirect T‑cell cytotoxicity. Obinutuzumab (anti‑CD20 mAb) is given once on Cycle 1 Day 1. Targets/pathways: MEN1703 inhibits PIM and FLT3 signaling pathways that support malignant B‑cell survival and proliferation, glofitamab (and obinutuzumab) target CD20 on B cells, with glofitamab also engaging CD3 on T cells to activate T‑cell–mediated killing. Types: small‑molecule kinase inhibitor, bispecific antibody, monoclonal antibody.